The ATP Sensitive Potassium Channel (KATP) Is a Novel Target for Migraine Drug Development

    Amalie Clement, Sarah Louise Christensen, Inger Jansen‐Olesen … Song Guo
    Studysummary This review suggests that blocking the ATP-sensitive potassium (K ATP) channel, particularly the Kir6.1/SUR2B subtype, may prove effective in treating migraines, with preclinical data supporting this approach; however, human studies are absent, and potential side effects could complicate clinical use.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Prospective Cardiovascular Evaluation with 24-Hour Holter and Ambulatory Blood Pressure Monitoring in Men Using 5-mg Oral Minoxidil for Androgenetic Alopecia Journal of The American Academy of Dermatology · 2022
    2. Potassium Channel Therapeutics at the Bedside Journal of Molecular and Cellular Cardiology · 2005